LINEZOLID

Linezolid

Composition: each tablet contains:

active substance: linezolid – 300 mg or 600 mg.

Therapeutic indications

Treatment of infections caused by sensitive anaerobic or aerobic gram-positive strains, including the infections accompanied by bacteremia, in case of the conditions listed below. Linezolid is not indicated for treatment of gram-negative infections. It is very important to immediately initiate specific gram-negative therapy, if an infection with gram-negative bacteria is suspected or documentally confirmed.

  1.    Pneumonia

Hospital-acquired pneumonia caused by Staphylococcus aureus (methicillin-sensitive and resistant isolates) or Streptococcus pneumoniae.

Community-acquired pneumonia caused by Streptococcus pneumonia, including the cases with concomitant bacteremia, or Staphylococcus aureus (only methicillin-sensitive isolates).

  2.    Skin and its structures infections

Complicated skin and its structures infections, including diabetic foot infections, without concomitant osteomyelitis, caused by Staphylococcus aureus (methicillin-sensitive and resistant isolates), Streptococcus pyogenes or Staphylococcus agalactiae.

Linezolid is not studied with respect to bedsores treatment.

Uncomplicated skin and its structures infections caused by Staphylococcus aureus (only methicillin-sensitive isolates) or Streptococcus pyogenes.

  3.    Vancomycin-resistant Enterococcus faecium infections

Vancomycin-resistant Enterococcus faecium infections, including the cases of concomitant bacteremia.

	АТС code
	J01XX08
	Pharmaceutical form
	coated tablets 300mg, 600 mg
	Storage conditions
	Store in protected from moisture and light place at temperature below 25°C.